Icotinib - Zhejiang Betta Pharma
Alternative Names: BPI-2009; BPI-2009C; BPI-2009H; Conmana; Icotinib hydrochlorideLatest Information Update: 22 May 2022
At a glance
- Originator Beta Pharma
- Developer Beta Pharma; Betta Pharmaceuticals Co Ltd; Zhejiang Betta Pharma
- Class 3-ring heterocyclic compounds; Alkynes; Antineoplastics; Crown ethers; Quinazolines; Small molecules
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Non-small cell lung cancer
- Phase II Brain metastases; Lung cancer; Nasopharyngeal cancer; Neurofibromatosis 2; Oesophageal cancer; Psoriasis
- No development reported Pancreatic cancer
Most Recent Events
- 08 Apr 2022 Interim efficacy data from a phase II ICAPE trial in non-small-cell lung cancer presented at the 113th Annual Meeting of the American Association for Cancer Research (AACR-2022)
- 07 Jan 2022 Registered for Non-small cell lung cancer (Adjuvant therapy) in China (PO) (Betta Pharmaceuticals pipeline,
- 01 Oct 2021 Zhejiang Betta Pharma completes a phase II trial in Non-small cell lung cancer (Adjuvant therapy) in China (PO) (NCT02044328)